Press Releases

Collaboration with Innovate UK Yields New Partners for Alzheimer’s Study Washington D.C., July 10, 2024- With groundbreaking creativity and breathtaking speed, this phase 3 competition, funded by Innovate UK, the UK’s innovation agency, is supporting organizations committed to improving dementia research using blood-based and digital biomarkers.   This competition received 14 proposals within one week, from […]

Washington D.C., July 8, 2024- Global Alzheimer’s Platform Foundation® (GAP) announced the appointment of Leigh Zisko, MPH as Chief Impact Officer and Tamiko MaGee-Rodgers, PhD, CCRP as the Director of Recruitment and Strategic Initiatives. In newly created global leadership roles, each will meaningfully contribute new perspectives and experience to GAP’s work in innovating clinical trial […]

Washington D.C., July 2, 2024- Global Alzheimer’s Platform Foundation® (GAP) President John Dwyer applauds the U.S. Food and Drug Administration (FDA) for its decision granting full traditional approval of Eli Lilly and Company’s Kisunla™ (donanemab), a disease-modifying Alzheimer’s treatment for adults with early symptomatic Alzheimer’s disease (AD).  “Today, the FDA grants full approval for donanemab, […]

Washington D.C., July 1, 2024- The Food and Drug Administration (FDA) unveiled a draft guidance document, “Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies,” which is open for public comment. This draft guidance points to improving participation from people who are traditionally underrepresented in clinical trials. John Dwyer, President […]

Global non-profit expands research network to the greater New Orleans areato improve access to research opportunities Washington D.C., June. 17, 2024- Global Alzheimer’s Platform Foundation® (GAP) is welcoming its first clinical research site from Louisiana into its network, Tandem Clinical Research of greater New Orleans. Tandem Clinical Research, a Prolerity Clinical Research Company site, advances […]

Washington D.C., June. 14, 2024- Global Alzheimer’s Platform Foundation® (GAP) proudly collaborated with The Global CEO Initiative on Alzheimer’s Disease (CEOi) to release the peer-reviewed publication of “Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease,” in Nature Reviews Neurology. Alzheimer’s blood tests have the […]

Washington D.C., June.10, 2024- Global Alzheimer’s Platform Foundation® (GAP) –applauds the U.S. Food and Drug Administration (FDA)’s acceptance of Eisai’s application for the subcutaneous maintenance dosing of Leqembi. With an action date set for January 25, 2025, this autoinjector will be used for weekly maintenance dosing and stands to reduce the burden on patients who are eligible to receive this disease-modifying therapy, as it can be used […]

Support from Scottish Parliament Underscores Its Significance Washington D.C., May 30, 2024-  The Global Alzheimer’s Platform Foundation® (GAP)  and the Scottish Funding Council’s Brain Health ARC have announced swift progress in the next steps of the Bio-Hermes Biomarker Data Challenge 2024, the research competition using the most comprehensive set of dementia biomarker data from ground-breaking […]

Washington D.C., Mar. 25, 2024- The Global Alzheimer’s Platform Foundation® (GAP) – which is focused on global game-changing dementia research – has chosen Scotland to host the Bio-Hermes Biomarker Data Challenge 2024, a research competition using the most comprehensive set of dementia biomarker data from ground-breaking early blood testing studies for Alzheimer’s disease. Researchers at […]

Washington D.C., Mar. 20, 2024- Labcorp announced its launch of new blood tests to detect the brain protein called tau. This announcement comes on the heels of the published results of the Bio-Hermes-001 study  which reveals a strong correlation between p-tau 217 with the presence of amyloid plaques in the brain, a diagnostic hallmark of […]

Washington D.C., Mar. 08, 2024- The U.S. Food and Drug Administration (FDA) announced today that it expects to convene a meeting of the Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) to discuss the Phase 3 TRAILBLAZER-ALZ 2 trial, which evaluated the efficacy and safety of Donanemab in early symptomatic Alzheimer’s disease. As the […]

Oral Presentation on Bio-Hermes to Take Place at Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (ADPD) Washington D.C., Mar 04, 2024- Global Alzheimer’s Platform Foundation®, (GAP) is pleased to share that new data from the ground-breaking blood-based and digital biomarker platform study, Bio-Hermes, will be shared by Douglas Beauregard, Project Director of Clinical Operations […]

The results of the Bio-Hermes study appear in Alzheimer’s & Dementia showing how new Alzheimer’s detecting blood tests perform across a broad range of races and ethnicities for the first time. Washington D.C., Feb. 28, 2024- The Global Alzheimer’s Platform Foundation®, (GAP) is releasing the first results from the Bio-Hermes-001 Study. This study in over […]

Researchers and Executives from more than 100+ Alzheimer’s and Parkinson’s clinical trial sites to collaborate on finding a cure for the devastating diseases NEW ORLEANS, La. (Feb. 26, 2024) — From February 28, 2024 through March 1, 2024, the Global Alzheimer’s Platform Foundation (GAP), an organization dedicated to speeding and improving the delivery of Alzheimer’s […]

The Global Alzheimer’s Platform Foundation’s® (GAP) 2023 Citizen Scientist Award© recipients include a philanthropic Mustang enthusiast, an “old-school” Veteran, an innovative volunteer with Parkinson’s disease and an Alzheimer’s advocate/ inspirational study partner. WASHINGTON, DC (Feb. 19, 2024) — Today, the Global Alzheimer’s Platform Foundation (GAP) proudly announced the 2023 National Citizen Scientist Awards® elevated honorees.  […]

The House of Representatives has passed The Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinson’s Act. GAP is celebrating this exciting news and commends all who helped to make this monumental achievement possible. We are grateful for the leadership of the House in ensuring that this legislation passed, especially from U.S. […]

We thank J&J for their leadership as they announced new efforts to combat Alzheimer’s disease, specifically their vaccine trial. In taking on this tau antibody and a tau-targeting vaccine, J&J is bringing hope to those impacted by Alzheimer’s disease, and addressing the need for cutting-edge research by launching this exciting trial. We are grateful for […]

The Global Alzheimer’s Platform Foundation (GAP) thanks trailblazer Sandra Day O’Connor, the first female to serve as a U.S Supreme Court Justice. While she paved the way for women leaders, she also raised awareness of the challenges of caregiving when she admirably retired from the Supreme Court in 2006 to care for her husband who […]

The Global Alzheimer’s Platform Foundation (GAP) thanks the First Lady for the grace and dignity she showed before and after President Carter’s term, and even more so these past six months after bravely announcing her dementia diagnosis. We join many around the world mourning her loss while acknowledging her quiet, positive impact over her 96 years.  […]

We applaud First Lady Jill Biden and the White House Gender Policy Council on the first ever initiative on Women’s Health Research, with a focus on ‘engaging the scientific, private sector, and philanthropic communities’. GAP is committed to ensuring that clinical research includes all people, and that includes ensuring that women are equally represented. We […]

Today, the US Senate confirmed President Biden’s nominee for National Institutes of Health (NIH) Director, Monica Bertagnolli, MD, who will lead the country’s top medical research institute. “We are thrilled that the US Senate has confirmed Dr. Monica Bertagnolli as the new Director of the NIH, as she is an esteemed leader with an impressive career […]

Washington D.C., Oct 23, 2023- Global Alzheimer’s Platform Foundation, (GAP) is pleased to share that new data from the ground-breaking blood-based and digital biomarker platform study, Bio-Hermes, will be shared by study partner Dr. Robin Wolz, of IXICO, at the 16th Clinical Trials on Alzheimer’s Disease (CTAD) conference. The data will be presented at Symposium […]

Revolutionary Studies, Record Breaking Collaboration, and Promising News on Biomarker Studies Top the Charts at AAIC   Washington D.C., Aug 31, 2023— Researchers and leaders from the Global Alzheimer’s Platform Foundation® (GAP) assembled with the world’s leading Alzheimer’s researchers, patient advocates, and clinicians at the annual Alzheimer’s Association International Conference (AAIC). From the memorable week, […]

The FDA’s approval comes following the recommendation of an FDA advisory committee, which voted unanimously for Leqembi’s full approval earlier this month WASHINGTON, DC, July 6, 2023 — Following a decision from the U.S. Food and Drug Administration (FDA) granting full traditional approval to Leqembi, a disease-modifying Alzheimer’s treatment from Eisai, Global Alzheimer’s Platform Foundation® (GAP) […]